Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by venture009on Oct 30, 2023 11:52am
166 Views
Post# 35707339

RE:08 Nov or 16 Nov 2023 good dates

RE:08 Nov or 16 Nov 2023 good datesIf there is an announcement I don't think it will happen until after the US Thanksgiving. My worry is the November 3 "chat" will be just that, nothing of relevance, which will once again disappoint the market. For the long time holders there is a legitimate concern that this management won't get us across the finish line in the form of a buyout, because over the years they have never been able to generate any shareholder value. The current action on the stock, specifically the volume, indicates there is very little interest. This is a concern from the point that if a buyout was imminent we would see a spike in volume. That's what I am waiting for. A first step towards all our hopes would be an AA, although I don't understand the FDA process to make this happen, I believe we need this to get the required involvement from a BP and institutions. Otherwise I worry we are headed in the same direction that occured after the positive Mbc data. 
<< Previous
Bullboard Posts
Next >>